CD274 and neoplasm: In MSS mCRC patients, PD-L1 mutations were shown to mediate immune escape of a subset of tumor subclones against avelumab, thereby affecting the efficacy of immunotherapy in a subset of patients expressing high-affinity FcγR3a (45).